Obermatt

Thermo Fisher Scientific

NYQ:TMO · US8835561023
Life Sciences Tools & ServicesLarge

360

46
EV / EBIT55
Price / Owner Earnings50
Owner Earnings Yield91
Dividend Yield88
Price/Sales53
EV / Gross Profit31
Price/Book51
Return on Capital59
Cash Return on Capital79
Return on Equity76
EBIT Margin67
Gross Profitability41
Cash Conversion23
Accruals7
Owner Earnings Margin79
Sales growth62
Profit Growth98
Long-Term EPS Growth34
Owner Earnings Growth43
Reinvestment64
Price momentum52
Debt load33
Refinancing54
Debt Payback35
Liquidity76
Analyst ratings72
Opinion Changes63
Price Target Upside69
Market mood86
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Thermo Fisher Scientific clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
TypePublic Company
ExchangeNYSE
Founded1960
Employees65,472
ISINUS8835561023
Last UpdateApr 2, 2026
Themes
ImmunologyGeneticsVaccinesHealth DiagnosticsBiomedical EngineeringAllergyBioinformaticsBiotechnologyLife Science

Description

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. The company serves customers working in pharmaceutical and biotech companies, hospitals an…

Analysis

Middle-of-the-road

Thermo Fisher Scientific Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is fair. You pay 21.7× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 7% yearly growth; analysts expect 9%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 8/20 on our value-creation score: creating some value.

What to watch: A large part of the company's book value is the price paid for past acquisitions. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
100
2023202420252026

All-time high

100

Jun 2026

All-time low

43

Jan 2024

Average rank

81

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
53
42
40
62
Price/Earnings
43
62
61
53
Price/Book
51
45
33
30
Dividend Yield
88
76
79
76
Value (overall)
88
83
78
83

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Thermo Fisher Scientific with its peers
Tempus AI
NSQ:TEM
28
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
OmniAb
NMQ:OABI
61
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Nautilus Biotechnology
NAQ:NAUT
26
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Maravai LifeSciences Holdings
NSQ:MRVI
35
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Fortrea
NSQ:FTRE
42
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Sotera Health
NSQ:SHC
59
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →